ZBIO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zenas BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.14 |
| 52 Week High | US$20.50 |
| 52 Week Low | US$16.50 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.8% | -4.0% | 0.6% |
| 1Y | n/a | 18.1% | 32.1% |
Return vs Industry: Insufficient data to determine how ZBIO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ZBIO performed against the US Market.
Price Volatility
| ZBIO volatility | |
|---|---|
| ZBIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ZBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ZBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 114 | Lonnie Moulder | zenasbio.com |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. Fundamentals Summary
| ZBIO fundamental statistics | |
|---|---|
| Market cap | US$688.01m |
| Earnings (TTM) | -US$54.76m |
| Revenue (TTM) | US$50.00m |
13.6x
P/S Ratio-12.5x
P/E RatioIs ZBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBIO income statement (TTM) | |
|---|---|
| Revenue | US$50.00m |
| Cost of Revenue | US$86.22m |
| Gross Profit | -US$36.22m |
| Other Expenses | US$18.53m |
| Earnings | -US$54.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | -72.45% |
| Net Profit Margin | -109.51% |
| Debt/Equity Ratio | 0% |
How did ZBIO perform over the long term?
See historical performance and comparison